NeuroBloc®/Myobloc®

Unique features and findings

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

This review outlines factors that differentiate botulinum toxin serotypes and focuses on the unique features of the commercially available form of BoNT-B (i.e., Myobloc®/NeuroBloc®). A series of preclinical studies in Cynomolgus monkeys are reviewed. Each of these studies used electrophysiologic measures of changes in the compound muscle action potential (CMAP) following supramaximal nerve stimulation to evaluate the direct effects of the toxin in the injected muscle, as well as the spread of the effects to non-injected muscles. The results of 14 studies were summarized, including several that compared the effects of equivalent doses of BoNT-A and BoNT-B injected into muscles on the opposite side of the same monkey. There is clear evidence that when equivalent doses of BoNT-A and BoNT-B are assessed, there is greater spread to both nearby and remote non-injected muscles associated with BoNT-A. Similar studies in the mouse model demonstrated that high, but non-lethal, doses of BoNT-A unilaterally injected into the foot resulted in spread of the effects across the midline to the opposite non-treated foot, while there was no evidence of bilateral effects with equivalent unilateral injections of BoNT-B. Finally, this review summarizes a series of studies in the trapezius and gastrocnemius muscles of monkeys demonstrating that when doses producing equivalent initial effects of BoNT-A and BoNT-B are compared, the duration of effects and the time course of recovery are almost identical across toxins.

Original languageEnglish (US)
Pages (from-to)690-696
Number of pages7
JournalToxicon
Volume54
Issue number5
DOIs
StatePublished - Oct 2009

Fingerprint

Muscle
Muscles
Haplorhini
Foot
Macaca fascicularis
Superficial Back Muscles
Botulinum Toxins
Action Potentials
Skeletal Muscle
incobotulinumtoxinA
rimabotulinumtoxinB
Injections
Recovery

Keywords

  • BoNT-A
  • BoNT-B
  • Compound muscle action potential
  • Cynomolgus monkey model
  • Myobloc/NeuroBloc

ASJC Scopus subject areas

  • Toxicology
  • Medicine(all)

Cite this

NeuroBloc®/Myobloc® : Unique features and findings. / Arezzo, Joseph C.

In: Toxicon, Vol. 54, No. 5, 10.2009, p. 690-696.

Research output: Contribution to journalArticle

@article{f4452b369e58442fa8205d1c9e443315,
title = "NeuroBloc{\circledR}/Myobloc{\circledR}: Unique features and findings",
abstract = "This review outlines factors that differentiate botulinum toxin serotypes and focuses on the unique features of the commercially available form of BoNT-B (i.e., Myobloc{\circledR}/NeuroBloc{\circledR}). A series of preclinical studies in Cynomolgus monkeys are reviewed. Each of these studies used electrophysiologic measures of changes in the compound muscle action potential (CMAP) following supramaximal nerve stimulation to evaluate the direct effects of the toxin in the injected muscle, as well as the spread of the effects to non-injected muscles. The results of 14 studies were summarized, including several that compared the effects of equivalent doses of BoNT-A and BoNT-B injected into muscles on the opposite side of the same monkey. There is clear evidence that when equivalent doses of BoNT-A and BoNT-B are assessed, there is greater spread to both nearby and remote non-injected muscles associated with BoNT-A. Similar studies in the mouse model demonstrated that high, but non-lethal, doses of BoNT-A unilaterally injected into the foot resulted in spread of the effects across the midline to the opposite non-treated foot, while there was no evidence of bilateral effects with equivalent unilateral injections of BoNT-B. Finally, this review summarizes a series of studies in the trapezius and gastrocnemius muscles of monkeys demonstrating that when doses producing equivalent initial effects of BoNT-A and BoNT-B are compared, the duration of effects and the time course of recovery are almost identical across toxins.",
keywords = "BoNT-A, BoNT-B, Compound muscle action potential, Cynomolgus monkey model, Myobloc/NeuroBloc",
author = "Arezzo, {Joseph C.}",
year = "2009",
month = "10",
doi = "10.1016/j.toxicon.2009.03.009",
language = "English (US)",
volume = "54",
pages = "690--696",
journal = "Toxicon",
issn = "0041-0101",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - NeuroBloc®/Myobloc®

T2 - Unique features and findings

AU - Arezzo, Joseph C.

PY - 2009/10

Y1 - 2009/10

N2 - This review outlines factors that differentiate botulinum toxin serotypes and focuses on the unique features of the commercially available form of BoNT-B (i.e., Myobloc®/NeuroBloc®). A series of preclinical studies in Cynomolgus monkeys are reviewed. Each of these studies used electrophysiologic measures of changes in the compound muscle action potential (CMAP) following supramaximal nerve stimulation to evaluate the direct effects of the toxin in the injected muscle, as well as the spread of the effects to non-injected muscles. The results of 14 studies were summarized, including several that compared the effects of equivalent doses of BoNT-A and BoNT-B injected into muscles on the opposite side of the same monkey. There is clear evidence that when equivalent doses of BoNT-A and BoNT-B are assessed, there is greater spread to both nearby and remote non-injected muscles associated with BoNT-A. Similar studies in the mouse model demonstrated that high, but non-lethal, doses of BoNT-A unilaterally injected into the foot resulted in spread of the effects across the midline to the opposite non-treated foot, while there was no evidence of bilateral effects with equivalent unilateral injections of BoNT-B. Finally, this review summarizes a series of studies in the trapezius and gastrocnemius muscles of monkeys demonstrating that when doses producing equivalent initial effects of BoNT-A and BoNT-B are compared, the duration of effects and the time course of recovery are almost identical across toxins.

AB - This review outlines factors that differentiate botulinum toxin serotypes and focuses on the unique features of the commercially available form of BoNT-B (i.e., Myobloc®/NeuroBloc®). A series of preclinical studies in Cynomolgus monkeys are reviewed. Each of these studies used electrophysiologic measures of changes in the compound muscle action potential (CMAP) following supramaximal nerve stimulation to evaluate the direct effects of the toxin in the injected muscle, as well as the spread of the effects to non-injected muscles. The results of 14 studies were summarized, including several that compared the effects of equivalent doses of BoNT-A and BoNT-B injected into muscles on the opposite side of the same monkey. There is clear evidence that when equivalent doses of BoNT-A and BoNT-B are assessed, there is greater spread to both nearby and remote non-injected muscles associated with BoNT-A. Similar studies in the mouse model demonstrated that high, but non-lethal, doses of BoNT-A unilaterally injected into the foot resulted in spread of the effects across the midline to the opposite non-treated foot, while there was no evidence of bilateral effects with equivalent unilateral injections of BoNT-B. Finally, this review summarizes a series of studies in the trapezius and gastrocnemius muscles of monkeys demonstrating that when doses producing equivalent initial effects of BoNT-A and BoNT-B are compared, the duration of effects and the time course of recovery are almost identical across toxins.

KW - BoNT-A

KW - BoNT-B

KW - Compound muscle action potential

KW - Cynomolgus monkey model

KW - Myobloc/NeuroBloc

UR - http://www.scopus.com/inward/record.url?scp=68849121142&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=68849121142&partnerID=8YFLogxK

U2 - 10.1016/j.toxicon.2009.03.009

DO - 10.1016/j.toxicon.2009.03.009

M3 - Article

VL - 54

SP - 690

EP - 696

JO - Toxicon

JF - Toxicon

SN - 0041-0101

IS - 5

ER -